Most prostate cancers rely on male sex hormones, known as androgens, to grow. As a result, standard treatment focuses on ...
Please provide your email address to receive an email when new articles are posted on . One journal reviewer told Donald P. McDonnell, PhD, the research should be “banned from the literature.” A ...
Trial in progress (XALute): Phase 3 study of xaluritamig vs investigator’s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant ...
Rubraca is now FDA-approved for BRCA mutation-associated mCRPC after prior androgen receptor-directed therapy, confirming its efficacy in the TRITON3 trial. The TRITON3 trial showed Rubraca ...
“Serial ctDNA testing gives us a moving picture, not a snapshot,” said first author Chinmay T. Jani, M.D., Chief Fellow, Hematology and Oncology, at Sylvester Comprehensive Cancer Center. “That has ...
A real-world clinicogenomic study of androgen receptor mutations and co-mutations in prostate cancer: Clinical implications. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...
Rucaparib received FDA approval for BRCA-mutated mCRPC after prior androgen receptor–directed therapy, based on the TRITON3 trial results. The trial demonstrated significant improvement in ...
To determine whether increased androgen receptor protein concentration has a causal role in the hormone sensitive-to-hormone refractory transition, we introduced epitope-tagged wild-type AR cDNA, by ...
A new study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene-commonly altered in prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results